First case series on the use of imiquimod for morphoea

Br J Dermatol. 2005 Oct;153(4):815-20. doi: 10.1111/j.1365-2133.2005.06776.x.

Abstract

Background: Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)-beta.

Objective: Our objective was to use imiquimod 5% cream (Aldara), an inducer of interferon-gamma, known to inhibit TGF-beta, to treat morphoea.

Methods: Patients with morphoea were treated with imiquimod and evaluated during their follow-up visits to 6 months.

Results: The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness.

Conclusion: This is the first case series describing the successful application of imiquimod in the management of morphoea.

MeSH terms

  • Administration, Cutaneous
  • Adolescent
  • Adult
  • Aged
  • Aminoquinolines / therapeutic use*
  • Child
  • Drug Evaluation
  • Female
  • Follow-Up Studies
  • Humans
  • Imiquimod
  • Interferon Inducers / therapeutic use*
  • Male
  • Middle Aged
  • Scleroderma, Localized / drug therapy*
  • Scleroderma, Localized / pathology
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Aminoquinolines
  • Interferon Inducers
  • Imiquimod